The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS

Basit Öğe Kaydı
dc.authoridYilmaz, Nafiye/0000-0002-4041-297X;
dc.contributor.authorInal, H. A.
dc.contributor.authorInal, Z. H. Ozturk
dc.contributor.authorYilmaz, N.
dc.contributor.authorTimur, H.
dc.contributor.authorOruc, A. S.
dc.contributor.authorKalem, M. N.
dc.contributor.authorHan, O.
dc.date.accessioned2025-10-24T18:09:34Z
dc.date.available2025-10-24T18:09:34Z
dc.date.issued2017
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractPurpose: To investigate the effects of formoterol (a beta2-adrenoreceptor agonist) on serum and peritoneal fluid VEGF, malondialdehyde (MDA) levels, and on VEGF-stained cell counts in the ovaries and endometrium of rats with ovarian hyperstimulation syndrome (OHSS) within the framework of immunohistochemical analysis. Materials and Methods: A total of 28 immature female Wistar rats were randomly divided into four groups. Three groups were given ten IU pregnant mare serum gonadotropin/day on days 22-25 of life. They were administered 30 IU hCG on day 26 of life to mimic OHSS. On days 26 and 27 of life, 24 mcg/kg/day formoterol in group 3 and 48 mcg/kg formoterol in group 4 were administered intraperitoneally per animal. Results: Although, there were no statistically significant differences between the groups in terms of serum and peritoneal fluid VEGF or MDA levels (serum VEGF: p = 0.281, peritoneal VEGF: p = 0.674, serum MDA: p = 0.543, peritoneal MDA: p = 0.506), there was a significant difference between the control and the OHSS placebo groups (p = 0.013) regarding the VEGF in the ovarian cortex. There was a significant difference between the control and the other groups in terms of ovarian stroma (p = 0.001), and there was also a statistically significant difference between the OHSS placebo and the other groups regarding VEGF in the endometrium (OHSS placebo vs. control group p = 0.002, OHSS placebo vs. the formoterol 24 mcg/kg group, p = 0.008, and OHSS-placebo vs. the formoterol 48 mcg/kg group, p = 0.001). Conclusions: Formoterol represents a potential novel strategy for the management of OHSS. Further studies, including those examining the dosage of formoterol, are warranted.
dc.identifier.doi10.12891/ceog3264.2017
dc.identifier.endpage128
dc.identifier.issn0390-6663
dc.identifier.issue1
dc.identifier.pmid29714880
dc.identifier.scopus2-s2.0-85015230086
dc.identifier.scopusqualityQ4
dc.identifier.startpage122
dc.identifier.urihttps://doi.org/10.12891/ceog3264.2017
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3713
dc.identifier.volume44
dc.identifier.wosWOS:000393628600025
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherI R O G Canada, Inc
dc.relation.ispartofClinical And Experimental Obstetrics & Gynecology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectOHSS; Prevention; VEGF; MDA; Formoterol
dc.titleThe effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu